Chester Springs, PA, United States of America

Robert L Hudkins

USPTO Granted Patents = 72 (Patent Applications = 7)

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 19 (Patent Applications = 19)

Average Co-Inventor Count = 3.6

ph-index = 13

Forward Citations = 513(Granted Patents)

Forward Citations (Not Self Cited) = 353(Oct 12, 2025)

Inventors with similar research interests:

Location History:

San Diego, CA (US) (2018)
Chester Springs, PA (US) (1995 - 2024)

Company Filing History:

Kyowa Hakko Kogyo Co., Ltd.

patents

5. 3 out of 262

Cancer Research Technology Limited

8. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2025

Loading Chart...

72 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12448392 - Spiropiperidine derivatives (2025-10-21),

2. 12441702 - Substituted 4-benzyl and 4-benzoyl piperidine derivates (2025-10-14),

3. 12098130 - 1,4-substituted piperidine derivatives (2024-09-24),

4. 11878982 - Spiropiperidine derivatives (2024-01-23),

5. 11878966 - Substituted 4-benzyl and 4-benzoyl piperidine derivates (2024-01-23),

6. 11702388 - 1,4-substituted piperidine derivatives (2023-07-18),

7. 11046707 - Spiropiperidine derivatives (2021-06-29),

8. 10919875 - Substituted 4-benzyl and 4-benzoyl piperidine derivatives (2021-02-16),

9. 10851057 - 1,4-substituted piperidine derivatives (2020-12-01),

10. 10414763 - Azaquinazoline inhibitors of atypical protein kinase C (2019-09-17),

11. 10221135 - 1,4-substituted piperidine derivatives (2019-03-05),

12. 10028956 - Methods of treating various cancers using an AXL/cMET inhibitor in combination with other agents (2018-07-24),

13. 10017496 - Uracil derivatives as AXL and c-MET kinase inhibitors (2018-07-10),

14. 9914731 - Pyrazolo[1,5-a]pyridine derivatives and methods of their use (2018-03-13),

15. 9914730 - Azaquinazoline inhibitors of Atypical protein Kinase C (2018-03-13),

Title: Robert L. Hudkins: Celebrated Inventor and Innovator in Pharmaceutical Chemistry

Introduction: Robert L. Hudkins, a distinguished inventor based in Chester Springs, PA, has made significant contributions to the field of pharmaceutical chemistry. With an impressive portfolio of 70 patents, he has dedicated his career to developing innovative compounds that target critical health issues.

Latest Patents: Among his most recent inventions are groundbreaking compounds known as 1,4-substituted piperidine derivatives. These compounds have been shown to act as fatty acid synthase inhibitors, providing potential therapeutic avenues for treating diseases associated with this enzyme. Furthermore, his patents include spiropiperidine derivatives, which also exhibit similar activity against fatty acid synthase. Hudkins has detailed methods for synthesizing these compounds, along with their pharmaceutical formulations, highlighting his commitment to both innovation and practical application.

Career Highlights: Throughout his career, Hudkins has played pivotal roles in prominent companies such as Cephalon, Inc. and 89bio, Inc. His efforts in these organizations have propelled advancements in drug development and therapeutic solutions, showcasing his expertise in the field.

Collaborations: Hudkins has collaborated with reputable colleagues, including Allison L. Zulli and Nadine C. Becknell. These partnerships have further enriched his research endeavors, fostering an environment of creativity and innovation that has led to the successful development of several patented compounds.

Conclusion: Robert L. Hudkins' impact on pharmaceutical chemistry is undeniable. His extensive patent portfolio and collaborative efforts underline his dedication to innovation and improving healthcare solutions. As he continues to develop novel compounds, Hudkins remains a prominent figure in the realm of scientific advancement.

This text is generated by artificial intelligence and may not be accurate.